CLINICAL TRIALS PROFILE FOR NOURIANZ
✉ Email this page to a colleague
All Clinical Trials for NOURIANZ
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05217498 ↗ | Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury | Not yet recruiting | Randy Trumbower, PT, PhD | Phase 1/Phase 2 | 2022-06-01 | Breathing brief, moderate bouts of low oxygen (acute intermittent hypoxia, AIH) trigger spinal plasticity and improve walking function after spinal cord injury (SCI). However, extracellular adenosine accumulates during hypoxia exposures and may undermine the efficacy of AIH training-induced walking recovery. The goal of the study is to understand how caffeine may augment the effects of AIH training on walking recovery and spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences) following SCI. |
| NCT05377424 ↗ | Adenosine 2A Receptor Antagonism and AIH in ALS | Not yet recruiting | ALS Association | Phase 1/Phase 2 | 2022-06-01 | The purpose of this research study is to determine the effects of a medication, istradefylline, in conjunction with breathing air with reduced oxygen for short periods of time (called acute intermittent hypoxia, or AIH), on breathing. This project will study breathing in people with amyotrophic lateral sclerosis (ALS) and unaffected, age-matched adults. Istradefylline is prescribed to increase movement in people with other neuromuscular conditions. A recently completed study found that people with ALS took deeper breaths, 60 minutes after using AIH. |
| NCT05377424 ↗ | Adenosine 2A Receptor Antagonism and AIH in ALS | Not yet recruiting | University of Florida | Phase 1/Phase 2 | 2022-06-01 | The purpose of this research study is to determine the effects of a medication, istradefylline, in conjunction with breathing air with reduced oxygen for short periods of time (called acute intermittent hypoxia, or AIH), on breathing. This project will study breathing in people with amyotrophic lateral sclerosis (ALS) and unaffected, age-matched adults. Istradefylline is prescribed to increase movement in people with other neuromuscular conditions. A recently completed study found that people with ALS took deeper breaths, 60 minutes after using AIH. |
| NCT05885360 ↗ | Istradefylline Effect Protocol on Parkinson's Disease Tremor | Recruiting | Kyowa Kirin, Inc. | Phase 4 | 2023-01-20 | This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in sub-optimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NOURIANZ
Condition Name
Clinical Trial Locations for NOURIANZ
Trials by Country
Clinical Trial Progress for NOURIANZ
Clinical Trial Phase
Clinical Trial Sponsors for NOURIANZ
Sponsor Name
